284 related articles for article (PubMed ID: 25619386)
1. Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Yang Z; Liu Y; Wei X; Zhou X; Gong C; Zhang T; Jin P; Xu S; Ma D; Gao Q
Curr Cancer Drug Targets; 2015; 15(3):215-26. PubMed ID: 25619386
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Yu Y; Zhang M; Zhang X; Cai Q; Hong S; Jiang W; Xu C
J Hematol Oncol; 2014 May; 7():39. PubMed ID: 24886678
[TBL] [Abstract][Full Text] [Related]
3. PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
Konishi H; Takagi A; Kurita A; Kaneda N; Matsuzaki T
BMC Cancer; 2012 Oct; 12():462. PubMed ID: 23046546
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
5. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
6. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
Correa RJ; Valdes YR; Peart TM; Fazio EN; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Carcinogenesis; 2014 Sep; 35(9):1951-61. PubMed ID: 24562574
[TBL] [Abstract][Full Text] [Related]
7. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
8. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
Wei X; Liu Y; Gong C; Ji T; Zhou X; Zhang T; Wan D; Xu S; Jin P; Yang X; Li X; Ma D; Yang Z; Gao Q
Anticancer Agents Med Chem; 2017; 17(8):1093-1101. PubMed ID: 28002999
[TBL] [Abstract][Full Text] [Related]
9. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.
Burleson KM; Casey RC; Skubitz KM; Pambuccian SE; Oegema TR; Skubitz AP
Gynecol Oncol; 2004 Apr; 93(1):170-81. PubMed ID: 15047232
[TBL] [Abstract][Full Text] [Related]
10. Mesothelial cells facilitate cancer stem‑like properties in spheroids of ovarian cancer cells.
Shishido A; Mori S; Yokoyama Y; Hamada Y; Minami K; Qian Y; Wang J; Hirose H; Wu X; Kawaguchi N; Nagumo S; Matsuura N; Yamamoto H
Oncol Rep; 2018 Oct; 40(4):2105-2114. PubMed ID: 30066911
[TBL] [Abstract][Full Text] [Related]
11. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
12. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
Liu B; Huang X; Li Y; Liao W; Li M; Liu Y; He R; Feng D; Zhu R; Kurihara H
BMC Cancer; 2019 Jul; 19(1):645. PubMed ID: 31262254
[TBL] [Abstract][Full Text] [Related]
13. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
[No Abstract] [Full Text] [Related]
14. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines.
Hiraishi Y; Wada T; Nakatani K; Tojyo I; Matsumoto T; Kiga N; Negoro K; Fujita S
Pathol Oncol Res; 2008 Mar; 14(1):39-43. PubMed ID: 18347929
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Parashar D; Nair B; Geethadevi A; George J; Nair A; Tsaih SW; Kadamberi IP; Gopinadhan Nair GK; Lu Y; Ramchandran R; Uyar DS; Rader JS; Ram PT; Mills GB; Pradeep S; Chaluvally-Raghavan P
Cancer Res; 2020 Dec; 80(24):5554-5568. PubMed ID: 33087324
[TBL] [Abstract][Full Text] [Related]
19. Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells.
Grunt TW
Cancer Lett; 2003 Jan; 189(2):147-56. PubMed ID: 12490307
[TBL] [Abstract][Full Text] [Related]
20. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
